Initiative for Safe Integration of Psychedelic Therapies

25 minutes ago 0

America is confronting a serious mental health crisis. Over 130 Americans die by suicide daily, including more than 20 veterans. Psychedelic-assisted therapies are emerging as an alternative for treatment-resistant conditions such as depression, PTSD, substance use disorders, and generalized anxiety disorder.

Unfortunately, patients are seeking these therapies abroad instead of receiving them in the U.S. The Trump administration made efforts to accelerate research, and the FDA granted Breakthrough Therapy designation to psychedelic-based drugs like psilocybin and MDMA. However, federal actions must intensify to make these therapies accessible.

Two years ago, the bipartisan Congressional Psychedelics Advancing Therapies (PATH) Caucus requested information on safely integrating psychedelic medicine into U.S. healthcare. While psychedelics aren’t miracle cures, safe and structured environments can transform patients’ experiences. Thus, federal policies are needed to establish national standards for safe therapeutic use.

Responses to the PATH request propose a pragmatic approach, focusing on accelerating medical development alongside robust safety measures. These involve setting national standards for service delivery and practitioner credentialing. Strong guidance systems and verification frameworks should be in place before FDA approvals of psychedelic therapies.

Labeling requirements, best practices for sessions, crisis response, and integration support are crucial. Addressing these issues would enable the American healthcare system to incorporate psychedelic-assisted therapies safely. It’s essential to establish a coherent standard set that ensures patient protection, equitable access, and benefits for those suffering severe mental and physical health challenges.

Jack Bergman from Michigan’s 1st Congressional District, along with Lou Correa from California’s 46th Congressional District, both co-chair the Congressional PATH Caucus.